The clinical trial supply industry is going through a period of rapid change, propelled by the aftermath of the pandemic and the rapid evolution of technology. Additionally, world-changing geopolitical events continue to impact supply chains across all sectors. Ahead of the 2024 Clinical Trial Supply Forum, Pharma IQ interviewed Advisory Board member and Event Chairman, Steven Jacobs, President of Global BioPharm Solutions LLC, and we are pleased to take this opportunity to share with you our annual review of the trends and complexities that are shaping and driving transformation across the -end-to-end clinical trial supply chain.
Download the Report to Uncover:
• Expert Analysis on Industry Evolution: Gain invaluable insights into the profound transformation of the clinical trial supply landscape, emphasising the shift towards proactive, strategic supply chain models and the integration of cutting-edge technologies like AI and IoT.
• Impact of Global Challenges on Supply Chains: Learn how recent geopolitical events and the aftermath of the pandemic have driven innovation, emphasising the need for resilience and agility in overcoming supply chain disruptions.
• Technological Advancements in Supply Management: Explore the role of digital transformation in revolutionising supply chain management, with a focus on automation, predictive analytics, and real-time decision-making to ensure the success and integrity of clinical trials.
• Sustainability and Efficiency as Core Priorities: Delve into the growing emphasis on eco-friendly logistics and the optimisation of resource use, highlighting sustainable practices and efficiency improvements as key drivers of future industry success.
Pharma IQ is pleased to take this opportunity to share the 2024 Clinical Trial Supply Forum Trends Report with you.
Please note: That all fields marked with an asterisk (*) are required.
Join us at the 2024 Clinical Trial Supply Forum to engage with your industry colleagues and contribute to shaping the future of the clinical trial supply industry, whilst optimising your own clinical trial strategy.